Characterization of Immunological Profile of Renal Transplant Patients Undergoing Induction Treatment With Thymoglobulin vs. IL-2 Receptor Antagonist Basiliximab

Mass General Brigham

Status: Completed

Conditions: Renal Transplantation

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT00842699

2008p000774

Genzyme

Details and patient eligibility

About

The goal of the study is to find out the effects of two different drugs used at the beginning of organ transplantation on different populations of immune cells in the body of patients.

Enrollment: 40 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• all patients considered for transplantation

Exclusion criteria

• none

Trial design

40 participants in 2 patient groups

1

Description:

patients receiving IL-2 receptor antagonist (Simulect) as induction treatment

2

Description:

patients receiving Thymoglobulin as induction treatment